{"disease":{"id":"late-onset-pompe-disease","name":"Late-onset Pompe disease","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":4,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"cipaglucosidase-alfa","indication_name":"Late-onset Pompe disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pombiliti","generic_name":"CIPAGLUCOSIDASE ALFA","company_name":"Amicus Therapeutics Europe Limited","drug_phase":"marketed","molecular_target":"Cation-independent mannose-6-phosphate receptor","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Pombiliti works by replacing the deficient acid alpha-glucosidase enzyme in patients with Late-onset Pompe disease."},{"drug_id":"avalglucosidase-alfa-ngpt","indication_name":"Late-onset Pompe disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"NEXVIAZYME","generic_name":"AVALGLUCOSIDASE ALFA-NGPT","company_name":"GENZYME CORP","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC]","quality_score":17,"revenue":null,"mechanism":""},{"drug_id":"cipaglucosidase-alfa-atga","indication_name":"Late-onset Pompe disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"POMBILITI","generic_name":"CIPAGLUCOSIDASE ALFA-ATGA","company_name":"AMICUS THERAP US","drug_phase":"marketed","molecular_target":"Cation-independent mannose-6-phosphate receptor","drug_class":"","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"miglustat","indication_name":"Lateonset Pompe disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zavesca","generic_name":"MIGLUSTAT","company_name":"AstraZeneca","drug_phase":"marketed","molecular_target":"Lysosomal alpha-glucosidase","drug_class":"Glucosylceramide Synthase Inhibitor [EPC]","quality_score":75,"revenue":null,"mechanism":"Zavesca works by inhibiting the enzyme glucosylceramide synthase, which is involved in the production of a toxic lipid that accumulates in cells of patients with certain lysosomal storage disorders."},{"drug_id":"avalglucosidase-alfa","indication_name":"Late-onset Pompe disease","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Neogaa","generic_name":"AVALGLUCOSIDASE ALFA","company_name":"Sanofi","drug_phase":"marketed","molecular_target":"","drug_class":"Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC]","quality_score":55,"revenue":null,"mechanism":"AVALGLUCOSIDASE ALFA breaks down glycogen in lysosomes to treat Pompe disease."}],"pipeline":[],"offLabel":[],"totalMarketed":5,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT06539169","title":"FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"xCures","has_results":false},{"nct_id":"NCT02765828","title":"Identification of Tongue Involvement in Late-Onset Pompe Disease","phase":"","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05431127","title":"High Dose Inspiratory Muscle Training in LOPD","phase":"NA","overall_status":"COMPLETED","enrollment_count":34,"lead_sponsor_name":"Duke University","has_results":false},{"nct_id":"NCT05083806","title":"MSOT in Pompe Disease","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT03347253","title":"STRIDE Study - A Study in Subjects With LOPD Who Are Currently Being Treated With ERT","phase":"","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Amicus Therapeutics","has_results":false},{"nct_id":"NCT02191917","title":"A Study of Respiratory Muscle Strength in Patients With Late-onset Pompe Disease (LOPD)","phase":"","overall_status":"TERMINATED","enrollment_count":8,"lead_sponsor_name":"BioMarin Pharmaceutical","has_results":true}],"total":6},"guidelines":[],"source":"Drug Landscape verified database"}